Federal Register Notice: FDA has determined the regulatory review period for Novo Nordisk’s Victoza is 3,370 days for extending a patent which claims the human drug product. Victoza (liraglutide (rDNA origin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. To view this notice, click here.
